Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SODIUM AMINOSALICYLATE vs MYAMBUTOL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Sodium aminosalicylate inhibits folic acid synthesis in Mycobacterium tuberculosis by competing with para-aminobenzoic acid (PABA) for the enzyme dihydropteroate synthase, thereby blocking bacterial growth.
Inhibits arabinosyl transferase, an enzyme involved in cell wall synthesis of mycobacteria, leading to inhibition of cell growth.
Tuberculosis (second-line therapy, in combination with other antituberculous agents)
Treatment of pulmonary tuberculosis in combination with other antituberculosis agents,Treatment of extrapulmonary tuberculosis
4 g orally three times daily (total daily dose 12 g) for tuberculosis treatment. Also available as 10 g in 250 m L for intravenous infusion over 5-6 hours, typically once daily.
15-25 mg/kg orally once daily (max 2.5 g/day); usual dose 20 mg/kg/day.
0.75-1.5 hours (parent drug); prolongs to 4-6 hours in renal impairment or with probenecid coadministration. Rapid acetylation phenotype reduces half-life by ~30%.
Terminal elimination half-life: 3-4 hours in normal renal function; prolonged to 7-15 hours in renal impairment.
Hepatic acetylation (N-acetyltransferase) and renal excretion of metabolites.
Partially metabolized in the liver via dealkylation to an aldehyde intermediate, which is further oxidized to a dicarboxylic acid. Approximately 50% of the drug is excreted unchanged in urine.
Renal: >80% as metabolites (acetylated and free), with 50-60% as N-acetyl-4-aminosalicylic acid; biliary/fecal: <1%.
Renal: 50% unchanged drug; 20% as metabolite (ethambutol carboxylic acid); 15% as aldehyde intermediate; 15% unknown; fecal: <10%.
50-60% bound to albumin; binding is saturable at high concentrations.
20-30% bound to albumin.
0.2-0.3 L/kg (distributes into total body water; low tissue penetration except inflamed pleural fluid and caseous granulomas).
1.6 L/kg; distributes widely into tissues, including erythrocytes and cerebrospinal fluid (with inflamed meninges).
Oral: 90-100% (rapidly absorbed from GI tract); no parenteral formulation available.
Oral: approximately 80% absorbed.
For GFR <30 m L/min: reduce dose to 4 g orally twice daily (total 8 g/day). For GFR <10 m L/min: administer 4 g orally once daily. No adjustment for GFR ≥30 m L/min.
Cr Cl 30-60 m L/min: 15-20 mg/kg daily; Cr Cl 10-29 m L/min: 15 mg/kg every 24-36 hours; Cr Cl <10 m L/min: 15 mg/kg every 48 hours.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: consider 50% dose reduction. Child-Pugh Class C: use with caution; consider further reduction or alternative therapy as pharmacokinetics are not well studied.
No specific Child-Pugh based adjustments; use with caution in severe hepatic impairment.
Children: 150-300 mg/kg/day orally divided into 3-4 doses, not to exceed 12 g/day. Intravenous: 150-200 mg/kg/day as a continuous infusion or in divided doses.
15-25 mg/kg orally once daily (max 1 g/day for children weighing <20 kg, otherwise 2.5 g/day).
Start at lower end of dosing range (e.g., 4 g orally twice daily) due to age-related decline in renal function. Monitor renal function and adjust per GFR-based guidelines. Caution with hepatic impairment.
Consider reduced initial dose based on renal function; monitor for optic neuritis.
None.
MYAMBUTOL may cause optic neuritis and decreased visual acuity, which may be dose-related and reversible upon discontinuation. Not recommended for use in children under 13 years of age.
May cause hepatotoxicity, hypersensitivity reactions (fever, rash, eosinophilia), gastrointestinal intolerance, and crystalluria. Monitor liver function tests and renal function periodically.
Optic neuritis (monitor visual acuity and color discrimination); hepatic toxicity; renal impairment (dose adjustment required); interaction with aluminum-containing antacids (decreased absorption).
Hypersensitivity to aminosalicylic acid or any component; severe renal impairment (Cr Cl < 10 m L/min).
Hypersensitivity to ethambutol; optic neuritis (unless benefit outweighs risk); children under 13 years of age (relative contraindication).
Take with or after meals to minimize gastrointestinal irritation. Avoid alcohol due to increased risk of hepatotoxicity and GI upset. No specific food interactions; but a low-fat diet may help reduce GI side effects.
No significant food interactions. However, administration with food may reduce gastrointestinal upset. Concurrent use with aluminum-containing antacids may decrease absorption; separate by at least 2 hours.
FDA Pregnancy Category C. First trimester: Limited data; animal studies show some teratogenicity at high doses; no adequate human studies; use only if clearly needed. Second and third trimesters: No specific known fetal risks; however, theoretical risk of kernicterus due to bilirubin displacement from albumin binding, though not confirmed with aminosalicylic acid.
Ethambutol (Myambutol) is classified as FDA Pregnancy Category B. Animal studies have not demonstrated teratogenic effects. Human data are limited but do not suggest a significant increase in major malformations. However, due to the risk of optic neuritis in the mother, use during pregnancy should be cautious and only if clearly needed.
Excretion into breast milk is unknown; due to potential for serious adverse reactions in nursing infants (e.g., hypersensitivity, gastrointestinal disturbance), decision should be made to discontinue nursing or the drug, taking into account importance of drug to mother.
Ethambutol is excreted into human breast milk in low concentrations; the estimated infant dose is approximately 2-4% of the maternal weight-adjusted dose. The milk-to-plasma ratio is approximately 0.57. The American Academy of Pediatrics considers ethambutol compatible with breastfeeding. Monitor the infant for signs of optic neuritis or gastrointestinal effects.
No established dose adjustment guidelines for pregnancy; pharmacokinetic changes (increased volume of distribution, increased renal clearance) may theoretically reduce serum concentrations; therapeutic drug monitoring is not routinely recommended but may be considered if efficacy is in question.
No specific dose adjustments are routinely recommended during pregnancy. However, pharmacokinetic changes in pregnancy (increased volume of distribution, enhanced renal clearance) may reduce serum concentrations; therapeutic drug monitoring is not standard but may be considered. Adjust dose based on renal function; usual dose is 15-25 mg/kg/day, not to exceed 2.5 g/day.
Sodium aminosalicylate (PAS) is a bacteriostatic agent used in combination therapy for multidrug-resistant tuberculosis. Administer with or after meals to reduce gastrointestinal upset. Monitor liver function tests and renal function periodically. Watch for hypersensitivity reactions, including fever, rash, and eosinophilia. Use with caution in patients with glucose-6-phosphate dehydrogenase deficiency due to risk of hemolytic anemia.
MYAMBUTOL (ethambutol) is a bacteriostatic agent used primarily in combination therapy for tuberculosis. Monitor for optic neuritis, which can cause decreased visual acuity, color blindness, and visual field defects; baseline and monthly visual acuity and color discrimination tests are mandatory. Dose adjustments required in renal impairment (Cr Cl <30 m L/min). Avoid in children <13 years old due to inability to monitor vision. May cause hyperuricemia; monitor uric acid levels in patients with gout.
Take this medication with or after food to reduce stomach upset.,Do not skip doses or stop taking this medication without consulting your doctor.,Report any signs of allergic reaction such as rash, fever, or swelling.,Avoid alcohol while taking this medication.,Keep all appointments for blood tests to monitor liver and kidney function.,Contact your doctor if you experience nausea, vomiting, abdominal pain, or yellowing of skin or eyes.
Take exactly as prescribed, usually once daily, with or without food.,Report any changes in vision immediately, such as blurred vision, difficulty seeing colors, or blind spots.,Avoid consuming alcohol; may increase risk of liver toxicity.,Do not stop taking this medication even if you feel better; complete full course to prevent resistance.,This drug may cause numbness or tingling in hands or feet; report these symptoms.,Inform your doctor if you have kidney disease, gout, or eye problems before starting treatment.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SODIUM AMINOSALICYLATE vs MYAMBUTOL, answered by our medical review team.
SODIUM AMINOSALICYLATE is a Antitubercular Agent that works by Sodium aminosalicylate inhibits folic acid synthesis in Mycobacterium tuberculosis by competing with para-aminobenzoic acid (PABA) for the enzyme dihydropteroate synthase, thereby blocking bacterial growth.. MYAMBUTOL is a Antitubercular Agent that works by Inhibits arabinosyl transferase, an enzyme involved in cell wall synthesis of mycobacteria, leading to inhibition of cell growth.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SODIUM AMINOSALICYLATE and MYAMBUTOL depend on the specific clinical indication. These are both Antitubercular Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SODIUM AMINOSALICYLATE is: 4 g orally three times daily (total daily dose 12 g) for tuberculosis treatment. Also available as 10 g in 250 m L for intravenous infusion over 5-6 hours, typically once daily.. The standard adult dose of MYAMBUTOL is: 15-25 mg/kg orally once daily (max 2.5 g/day); usual dose 20 mg/kg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SODIUM AMINOSALICYLATE and MYAMBUTOL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SODIUM AMINOSALICYLATE is classified as Category C. FDA Pregnancy Category C. First trimester: Limited data; animal studies show some teratogenicity at high doses; no adequate human studies; use only if clearly needed. Second and th. MYAMBUTOL is classified as Category C. Ethambutol (Myambutol) is classified as FDA Pregnancy Category B. Animal studies have not demonstrated teratogenic effects. Human data are limited but do not suggest a significant . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.